Arrowhead Research | ARWR - Cash And Equivalent


Arrowhead Research reported $129.79M in Cash and Equivalent for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 1.38B
Cash and Equivalent USD 129.79M
Current Assets USD 946.92M
Current Liabilities USD 194.53M
Debt USD 388.24M
EBIT USD -165.55M
EBITDA USD -159.33M
Employees 609
EPS Earnings Per Share USD -1.26
Equity Capital and Reserves USD 522.31M
Gross Profit on Sales USD 27.77M
Interest Expense on Debt USD 24.38M
Interest Income USD 9.62M
Loan Capital USD 200.33M
Market Capitalization USD 3.51B
Net Income USD -175.24M
Operating Expenses USD 193.32M
Operating Profit USD -165.55M
Ordinary Share Capital USD 138.14M
PE Price to Earnings USD 436.79
Pre-Tax Profit USD -179.09M
Sales Revenues USD 27.77M
Selling and Administration Expenses USD 30.95M
Stock USD -173.09M
Trade Creditors USD 33.05M
Trade Debtors USD 9.7M

Cash And Equivalent Change Date
Agios Pharmaceuticals USD 80.87M 1.91M Jun/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Arrowhead Research USD 129.79M 55.92M Jun/2025
Incyte USD 2.42B 13.08M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
Ligand Pharmaceuticals USD 67.67M 189.22M Jun/2025
Merck USD 8.01B 622M Jun/2025
Moderna USD 1.28B 344M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
TG Therapeutics USD 278.86M 146.72M Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025
Xencor USD 44.44M 4.77M Jun/2025